Drugs / quadrivalent influenza vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05526716 | Sep 2022 → Jun 2023 | streptococcal pneumonia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | quadrivalent influenza vaccine | “This phase 3 study evaluated the safety, tolerability, and immunogenicity of V116 when administered concomitantly with quadrivalent influenza vaccine (QIV) in adults.” PMID 40714528 ↗ Jul 2025 |
| Known as | QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05526716 ↗ |
| Modality | Vaccine | “quadrivalent influenza vaccine (QIV)” NCT05526716 ↗ |
| Route | Intramuscular | “Participants will receive a single 0.5 mL IM injection of QIV” NCT05526716 ↗ |